Back to About

OUR MANAGEMENT

Dr Tom Lin

MBA MMed PhD (Med)

Dr. Tom Lin (Yu-Hsin Lin) is the Founder, Chairman, and Chief Executive Officer of Belite Bio. Dr. Lin is also the Founder of Lin BioScience, Inc. (TPEx: 6696), our ultimate controlling shareholder.  Prior to founding Belite Bio, Dr. Lin was executive officer of several biotech companies, including Lin BioScience, Inc. Dr. Lin received his master’s degree in Medicine and PhD in Medicine from University of Sydney, and his MBA from Columbia University, London Business School, and University of Hong Kong.

AFFILIATIONS

Prof Hendrik Scholl

MD

Prof Hendrik Scholl, MD, has served as the Chief Medical Officer of Belite Bio since September 2024. He is a clinically active retinal expert with more than two decades of expertise in treating retinal diseases, including Stargardt disease and age-related macular degeneration. Dr. Scholl served as the founding and scientific co-director of the Institute of Molecular and Clinical Ophthalmology Basel (IOB) and Chair of the Department of Ophthalmology of the University Hospital Basel. He currently serves as President of the European Vision Institute (EVI), Chairman of EVICR.net and its Expert Committee on Retinal Dystrophies, and Founder and President of ARVO-SWISS. In academia, Dr. Scholl has held leadership roles at key institutions, notably as Professor of Ophthalmology and Endowed Chair at the Wilmer Eye Institute of Johns Hopkins University Medical School, where he also led the Retinal Degeneration Clinic and the Visual Neurophysiology Service. Dr. Scholl is the coordinating principal investigator of the largest natural history study of Stargardt disease (ProgStar Study). He holds an honorary doctorate from Semmelweis University in Budapest, Hungary, and is Adjunct Professor at the Medical University of Vienna, Austria. Dr. Scholl graduated from the Eberhard-Karls-University Tübingen, Germany, with a Doctor of Medicine and Master of Arts. He was awarded a research fellowship from the German Research Foundation (DFG) at Moorfields Eye Hospital and Institute of Ophthalmology, University College London (UCL), United Kingdom, and later a DFG Heisenberg Professorship for Macular Diseases at the Eye Clinic of the Rheinische Friedrich-Wilhelms-University Bonn, Germany.

AFFILIATIONS

Dr Nathan Mata

PhD

Dr. Nathan L. Mata has served as the Chief Scientific Officer of Belite Bio since November 2021. Prior to joining Belite Bio, Dr. Mata was the principal consultant of clinical development sector of Halloran Consulting Group, clinical research and operations consultant of Kubota Vision Inc. (formerly Acucela Inc.), Chief Operating Officer and Director of R&D of  Trethera Corporation, and Vice President of R&D of Sirion Therapeutics. Dr. Mata received his master’s degree in Biochemistry and PhD in Neurobiology from University of Texas at San Antonio.

AFFILIATIONS

Hao-Yuan Chuang

CFA MBA FRM

Mr. Hao-Yuan Chuang has served as the Chief Financial Officer of our Company since April 2020 and Director of Belite Bio since November 2021. Prior to joining Belite Bio, Mr. Chuang served as Chief Financial Officer of Lin BioScience, Inc. (TPEx: 6696), our ultimate controlling shareholder, Investment Director of Suning International Limited, and Portfolio Manager of The People’s Insurance Company (Group) of China Limited (HKG: 1339). Mr. Chuang received his MBA from Columbia University, London Business School, and the University of Hong Kong. Mr. Chuang is also a Chartered Financial Analyst and Financial Risk Manager.

AFFILIATIONS

OUR BOARD

Dr Tom Lin

MBA MMed PhD (Med)

Dr. Tom Lin (Yu-Hsin Lin) is the Founder, Chairman, and Chief Executive Officer of Belite Bio. Dr. Lin is also the Founder of Lin BioScience, Inc. (TPEx: 6696), our ultimate controlling shareholder.  Prior to founding Belite Bio, Dr. Lin was executive officer of several biotech companies, including Lin BioScience, Inc. Dr. Lin received his master’s degree in Medicine and PhD in Medicine from University of Sydney, and his MBA from Columbia University, London Business School, and University of Hong Kong.

AFFILIATIONS

Hao-Yuan Chuang

CFA MBA FRM

Mr. Hao-Yuan Chuang has served as the Chief Financial Officer of our Company since April 2020 and Director of Belite Bio since November 2021. Prior to joining Belite Bio, Mr. Chuang served as Chief Financial Officer of Lin BioScience, Inc. (TPEx: 6696), our ultimate controlling shareholder, Investment Director of Suning International Limited, and Portfolio Manager of The People’s Insurance Company (Group) of China Limited (HKG: 1339). Mr. Chuang received his MBA from Columbia University, London Business School, and the University of Hong Kong. Mr. Chuang is also a Chartered Financial Analyst and Financial Risk Manager.

AFFILIATIONS

Hung-Wei Chen

MS

Ms. Hung-Wei Chen has served as Belite Bio’s Director since November 2021. Currently, she is the Chief Operating Officer of Lin BioScience, Inc. (TPEx: 6696), our ultimate controlling shareholder. Ms. Chen received her Master of Science in Medicinal Chemistry from National Taiwan University. Ms. Chen is also a certified pharmacist.

AFFILIATIONS

Wan-Shan Chen

Ms. Wan-Shan Chen has served as Belite Bio’s Director since November 2021. Currently, she is a finance executive of Lin BioScience, Inc. (TPEx: 6696), our ultimate controlling shareholder. Ms. Chen received her master’s degree in Accounting from National Taipei University. Ms. Chen is also a certified public accountant in Taiwan.

AFFILIATIONS

Prof John Longo

PhD MBA CFA

Prof. John M. Longo has served as Belite Bio’s Independent Director since April 29, 2022. Prof. Longo is a Finance and Economics faculty member at Rutgers Business School, where he is currently professor of practice and a CFA Charter holder. Dr. Longo has also been a visiting professor of finance at Columbia Business School, London Business School, and University of Hong Kong’s joint EMBA Global program. Dr. Longo served as Chief Investment Officer for the MDE Group and Beacon Trust, and has also served as President of Cliff House Capital Management and its predecessor, Cyborg Capital Management. Prof. Longo received his PhD and MBA in Finance from Rutgers Business School. 

AFFILIATIONS

Prof Gary Biddle

PhD MBA

Prof. Gary C. Biddle has served as Belite Bio’s Independent Director since April 29, 2022. He is the professor of financial accounting at The University of Melbourne and visiting professor at Columbia University, London Business School, and University of Hong Kong.  In academic leadership, Professor Biddle served as Dean and Chair Professor at University of Hong Kong, and as Academic Dean, Chair Professor, Council and Senate member at Hong Kong University of Science and Technology. Professionally, he is a member of the AICPA, Australian Institute of Company Directors, CPA Australia, and HKICPA. Professor Biddle has served as editor and editorial board member of premier academic journals and as American Accounting Association Executive Board member, Vice-President and President-Elect nominee on the Accounting Hall of Fame Selection Committee, Financial Reporting Review Panel of the Financial Reporting Council of Hong Kong, HKICPA Council, Accreditation and Financial Reporting Standards Committees of HKICPA, and Hong Kong Institute of Directors Training Committee. Professor Biddle is a leading expert in financial and management accounting, value creation, economic forecasting, corporate governance, and performance metrics, including EVA®. He also serves as Non-Executive Director of Kingdee International Software (SEHK: 00268), as Independent Non-Executive Director and Audit and Risk Committee Chair of Shui-On Land Limited (SEHK: 00272), as Independent Non-Executive Director and Audit and Finance Committee Chair of Real Pet Food Company (New Hope Group), and he previously served as Remuneration Committee Chair of Chinachem Group. Professor Biddle earned his MBA and PhD in Accounting at University of Chicago.

AFFILIATIONS

Ita Lu

MS

Mr. Ita Lu has served as Belite Bio’s Independent Director since April 29, 2022. Mr. Lu is the Managing Partner of Taiwania Capital. Prior to joining Taiwania Capital, Mr. Lu served as Vice President of Business Development and Investor Relations of Etana Biotech, Head of greater China healthcare of KGI Securities, Equity Research Analyst of greater China healthcare of Yuanta Research, and Investment Manager of China Investment Development Corp. (SEHK: 204) and China Development Industrial Bank. Mr. Lu received his master’s degree in Biotechnology from Johns Hopkins University.

AFFILIATIONS